Nodality Launches PathPro™ Product Line Based on Leading Single Cell Network Profiling (SCNPTM) Platform to Enhance Pharmaceutical R&D

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--

Nodality, Inc., which is focused on solving drug development challenges, announced today the launch of its PathPro™ product line. PathPro products leverage the unique capabilities of Nodality's proprietary Single Cell Network Profiling (SCNP) technology, offering predefined multiparametric flow cytometry-based experimental panels. These panels allow us to study customer inhibitor activity and identify disease subgroups and differential responses in pathways or diseases. Nodality has introduced its first three PathPro products – the PathPro™ JAK-STAT panel, PathPro™ TLR and the PathPro™ AML panels – and these will be followed by additional products throughout 2015.

“Nodality's SCNP technology has been successfully applied and proven in autoimmune diseases, hematological cancers, and immuno-oncology. Based on this substantial and growing track record, we are expanding our offerings by introducing predefined experimental panels in cost-effective and highly targeted areas,” said Laura Brege, CEO and President of Nodality, Inc. “We believe the launch of our new PathPro products will accelerate familiarity with our technology advantages among our target customer base – pharmaceutical and life science companies – and lead to further demand for our customized services based on each customer's initial experience with the PathPro products.”

Nodality's PathPro products are based on the Company's broad knowledge and experience in diverse signaling pathways and in interrogating signaling at the single cell level in numerous cell types. For each PathPro product, customers are able to select modulators, pathways, cell types and donor sample types to be applied in targeted, small-scale studies. The results provide critical insights into the functional impact of drug candidates in disease sub-groups and differential response, pathway-specific profiles and/or disease profiles, while addressing mechanism of action (MOA), efficacy (IC50s) and comparison of compound activities.

Nodality's first three PathPro products are:

		•		PathPro™ JAK-STAT panel
				Nodality's PathPro Janus Kinase-Signal Transducer and Activator of Transcription (JAK-STAT) panel enables simultaneous measurements of signaling and compound activity in different cell subsets (monocytes, lymphocytes, and B and T cells) in the context of JAK-STAT signaling. Performance of modulators (interleukins, interferons and GM-CSF) is measured via readouts in the activity of the primary STAT protein signals. The JAK-STAT signaling pathway is essential for hematopoiesis and plays a central role in hematological malignancies and in the pathogenesis of autoimmune diseases, such as rheumatoid arthritis, systemic lupus erythematosus, and inflammatory bowel disease. For more information on the PathPro JAK-STAT panel, please visit http://nodality.com/products-standard-jak-stat.html.
		•		PathPro™ TLR panel
				Nodality offers the PathPro Toll-Like Receptor (TLR) panel for evaluation of B cell subsets and monocytes. The panel is designed to simultaneously measure signaling and compound activity in different cell types in the context of TLR signaling. Tight regulation of TLR-mediated signaling is critical for the maintenance of healthy immune responses; aberrant signaling through TLRs is associated with autoimmune disorders. For more information on the PathPro TLR panel, please visit http://nodality.com/products-standard-tlr.html.
		•		PathPro™ AML panels
				Nodality is offering a PathPro Acute Myeloid Leukemia (AML) Signaling and an AML Apoptosis panel. These panels can be used to study the potency, MOA, specificity and response to treatment in AML patients as single agents or in combinations. Nodality's SCNP platform has been used to characterize biological pathways associated with in vitro resistance or sensitivity to chemotherapeutics commonly used in AML. For more information on the PathPro AML panels, please visit http://nodality.com/products-disease-offerings.html.

About Single Cell Network Profiling

Nodality's proprietary Single Cell Network Profiling (SCNP) technology, a multiparametric flow cytometry-based platform, provides robust, human cell-based translational models of disease, drug activity and patient responses. SCNP reveals complex biology by characterizing cell signaling networks in millions of cells at the single cell level. SCNP technology, coupled with Nodality's proprietary data analysis and visualization tools, uniquely reveals complex functional biology to inform more effective drug development decisions thereby creating a competitive advantage.

Originally developed at Stanford University, SCNP does not require physical isolation of cell subsets and therefore provides real time information on cell-cell interactions, identifies the functional signaling capacity of rare cell subsets (such as drug-resistant cells and stem cell populations) reveals the functional consequences of epigenetic mutations and enables the interrogation of immune cell communication and dysfunction in disease.

About Nodality

Nodality is a life science company whose technology platform, SCNP, bridges the gap left by traditional R&D approaches. Nodality provides clinically actionable solutions throughout the full discovery and development process, including disease profiling, drug profiling, clinical development, and life cycle management. Nodality's team has expertise in identifying solutions across a broad therapeutic landscape, with a focus on immunology and oncology, including immuno-oncology. Nodality has established multi-year strategic collaborations with UCB Pharma S.A. (Euronext Brussels: UCB), Pfizer PFE and Johnson & Johnson JNJ, utilizing its SCNP technology to assist the discovery and development of new therapeutic compounds. Major investors include Kleiner Perkins, TPG Biotech, Maverick, Pfizer, and LabCorp.

For more information on Nodality, please visit www.nodality.com.